Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report)’s share price fell 1.4% on Tuesday . The stock traded as low as C$8.74 and last traded at C$8.74. 200 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 586 shares. The stock had previously closed at C$8.86.
Neuren Pharmaceuticals Stock Down 1.4 %
The company has a fifty day moving average of C$8.11 and a two-hundred day moving average of C$8.67.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Featured Articles
- Five stocks we like better than Neuren Pharmaceuticals
- What is a penny stock? A comprehensive guide
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What Are the FAANG Stocks and Are They Good Investments?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
